West Pharma Guides FY Sales to $3.35B-$3.38B, Above Consensus
WST sits 71% above its 52-week low of $211.1.
Summary
West Pharmaceutical Services issued FY sales guidance of $3.35B-$3.38B, a range that likely exceeds current analyst expectations. The company also raised its annual profit forecast, citing strong demand for injectable drug components. The stock is trading near its 52-week high, reflecting market optimism following a swift recovery from a May cybersecurity incident, the appointment of a new executive in June, and a 10-year partnership renewal with Daikyo Seiko in mid-July. The guidance provides concrete numbers that validate the upward momentum and could drive further price appreciation. Watch for the full earnings release for margin and EPS details.
At the time of this announcement, WST was trading at $360.20 on NYSE in the Life Sciences sector, with a market capitalization of approximately $25.3B. The 52-week trading range was $211.10 to $367.66. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.